Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesFinished GoodsGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityNon-Current AssetsNon-Current DebtOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Raw MaterialsReceivablesRetained EarningsShareholder's EquityTotal Current LiabilitiesTotal DebtTotal LiabilitiesTreasury SharesWork In Process
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Cytosorbents (CTSO) Retained Earnings (2016 - 2025)

Cytosorbents (CTSO) has disclosed Retained Earnings for 14 consecutive years, with -$3.8 million as the latest value for Q3 2025.

  • For the quarter ending Q3 2025, Retained Earnings rose 98.7% year-over-year to -$3.8 million, compared with a TTM value of -$3.8 million through Sep 2025, up 98.7%, and an annual FY2024 reading of $4.3 million, up 703.29% over the prior year.
  • Retained Earnings was -$3.8 million for Q3 2025 at Cytosorbents, up from -$4.0 million in the prior quarter.
  • Across five years, Retained Earnings topped out at $6.2 million in Q3 2022 and bottomed at -$296.4 million in Q3 2024.
  • Average Retained Earnings over 5 years is -$119.7 million, with a median of -$4.0 million recorded in 2025.
  • Peak annual rise in Retained Earnings hit 18960.32% in 2022, while the deepest fall reached 39833.18% in 2022.
  • Year by year, Retained Earnings stood at -$221.2 million in 2021, then fell by 14.83% to -$254.0 million in 2022, then surged by 100.21% to $529321.0 in 2023, then skyrocketed by 703.29% to $4.3 million in 2024, then tumbled by 190.4% to -$3.8 million in 2025.
  • Business Quant data shows Retained Earnings for CTSO at -$3.8 million in Q3 2025, -$4.0 million in Q2 2025, and $1.5 million in Q1 2025.